Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metronomic capecitabine in metastatic gastrointestinal solid tumors
2009-009919-21Phase 2Terminated
- Sponsor
- Fondazione Luigi Maria Monti IDI-IRCCS
- Start
- Nov 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine in colorectal cancer (CRC), gastric cancer (GC), cholangiocarcinoma (CCA) and 1 more, sponsored by Fondazione Luigi Maria Monti IDI-IRCCS. Primary endpoints: Time to progression and Serum angiogenic and inflammatory biomarkers. Started Nov 2009; status: terminated.
02
Drugs
capecitabine
03
Conditions
colorectal cancer (CRC)gastric cancer (GC)cholangiocarcinoma (CCA)pancreatic cancer (PC)
Beyond the preview
Go deeper on 2009-009919-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-009919-21.